Zion Pharma Signs an Agreement with Roche to Develop and Commercialize ZN-A-1041 for HER2-Positive Breast Cancer
Shots:
- Zion will receive ~$70M up front & additional fees upon achievement of near-term milestones, ~$610M in development, regulatory & sales-based milestones along with royalties on sales. Roche will lead the development, manufacturing, and commercialization of ZN-A-1041 globally
- Roche obtains the global rights to Zion’s ZN-A-1041, an orally administered selective tyrosine kinase inhibitor targeting HER2 which is currently being studied in an ongoing P-I trial at multiple sites in the US and China
- ZN-A-1041 was designed to be blood-brain-barrier-penetrant & is indicated to treat or prevent the onset of brain metastases in patients with HER2+ metastatic breast cancer
Ref: Businesswire | Image: Zion Pharma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
